| Name | Title | Contact Details |
|---|
AlphaRx, Inc. is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
You can depend on us. Our mission is to provide quality equipment services and repairs to our valued customers across the U.S. and Canada.
Biorasi is an award-winning full service, global Clinical Research Optimized (CRO). From project design to execution success, optimization is engrained in ProAct+. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world. Powered by ProAct+, Biorasi`s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world.
Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.